Personalis, Inc. Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and Its Microenvironment From a Single Sample

Personalis, Inc., a leader in advanced genomics for precision oncology, today announced the launch of its universal cancer immunogenomics platform, ImmunoID NeXT„¢. This is the first platform to enable comprehensive analysis of both a tumor and its microenvironment from a single sample.

Personalis CEO, John West, said, While the success of checkpoint blockade has been hugely promising, its increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomics. With ImmunoID NeXT, its now possible to characterize the complex interactions between the tumor cells and immune cells of the microenvironment using a single platform. This means researchers no longer have to make the difficult choice of which biomarkers to analyze due to sample limitations, particularly when dealing with FFPE specimens.

The unique design of the ImmunoID NeXT Platform facilitates the delivery of therapeutic and diagnostic biomarker information across ~20,000 genes from DNA and RNA, including:

  • Neoantigen identification and characterization
  • Human leukocyte antigens (HLA) typing
  • Tumor infiltrating adaptive immune cells
    • T-cell receptor (TCR) repertoire (α, β, γ, and δ chains)
    • B-cell receptor (BCR) repertoire (heavy and light chains)
  • Tumor infiltrating innate immune cells
  • Immune response and tumor escape mechanisms
  • Neoantigen load and tumor mutational burden (TMB)
  • Microsatellite instability (MSI) status
  • Oncoviral detection
  • Germline genomic variation

Personalis is offering pharmaceutical customers the opportunity to participate in an Early Access Program beginning in January, 2019. The company also anticipates the release of a clinical diagnostic test based on this platform in 2019.

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 

Personalis will be presenting new data at the Society for Immunotherapy of Cancers (SITC) Annual Meeting in Washington, D.C., November 8-11, 2018. Personalis representatives will also be available to discuss the ImmunoID NeXT Platform at the companys exhibit (Booth #617).

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The companys ImmunoID NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

Personalis, Inc.
Jennifer Havlek, 650-752-1300
[email protected]
www.personalis.com

 Stay Updated To Save Money & Time. Join Our Free Newsletter 
. Indepth Analysis & Opinion       . Interviews      . Exclusive Reports  
. Free Digital Magazines      News & updates      . Event Invitations 
                     
& Much More Delivered To Your Inbox For Free.
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

 
Close
Stay Updated To Save Money & Time. Join Our Free Newsletter. 
. Indepth Analysis & Opinion       Interviews          . Exclusive Reports 
. Free Digital Magazines        . News & updates        . Event Invitations
& Much More Delivered To Your Inbox For Free. 
Submit
We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.
 
Close